| 摘要 |
This invention relates to N-acylamino aryl derivatives of the general formula (I), wherein R1 is halogen, halogen-(C1-C6)-alkyl, cyano, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy; R21, R22, R23 and R24 independently from each other are selected from the group consisting of hydrogen, (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, hydroxy, C1-C6-alkoxy or -CHO; R3 is hydrogen or C1-C3-alkyl; R4, R5 independently from each other are selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-alkoxy or -COO(C1-C6) alkyl; or R4 and R5 form together with the C-atom to which they are attach a C3-C7-cycloalkyl ring; R6 is -CO-NR7R8; -COO(C1-C6)- alkyl, -CN, -NR2 or -NHC(O)R; R7 and R8 independently from each other are selected from the group consisting of hydrogen, C1-C6- alkyl, NH2 or hydroxy; R is hydrogen or C1-C6-alkyl; n is 0, 1, 2 or 3. X is -CHRO, -OCHR, -CH2S-, -SCH2-, -CH2CH2-, -CH=CH- or -CˆC-; and to pharmaceutically active acid addition salts thereof. It has been found that the compounds of general formula (I) are selective monoamine oxidase B inhibitors and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B inhibitors, for example for the treatment of AlzheimerâÇÖs disease or senile dementia.
|
